Histamine-induced airway mucosal exudation of bulk plasma and plasma-derived mediators is not inhibited by intravenous bronchodilators.
Experimental data suggest the possibility that common bronchodilators, such as the xanthines and beta 2-adrenoceptor agonists, may produce microvascular anti-permeability effects in the subepithelial microcirculation of the airways. In this study, we have examined the effect of bronchodilators given intravenously on exudation of different-sized plasma proteins (albumin and fibrinogen) and the generation of plasma-derived peptides (bradykinins) in human nasal airways challenged with histamine. In a double-blind, crossover, placebo-controlled and randomised trial, 12 normal volunteers were given i.v.infusions of terbutaline sulphate, theophylline and enprofylline to produce therapeutic drug levels. The effect of topical nasal provocation with histamine was closely followed by frequently nasal lavage with saline. The lavage fluid levels of albumin, fibrinogen and bradykinins increased significantly after each histamine provocation. The ratio of albumin-to-fibrinogen in plasma and the lavage fluid was 24 and 56, respectively, indicating that topical histamine provocation induced a largely non-sieved flux of macromolecules across the endothelial-epithelial barriers. The systemically administered drugs did not affect the nasal symptoms (sneezing, secretion and blockage), nor did they significantly reduce the levels of plasma proteins and plasma-derived mediators in the nasal lavage fluids. The present data suggest that systemic xanthines and beta 2-adrenoceptor agonists, at clinically employed plasma levels, may not affect the microvascular (and epithelial) exudative permeability and the bradykinin forming capacity of human airways.
Svensson
C
C
Department of Oto-Rhino-Laryngology, University Hospital, Lund, Sweden.
Alkner
U
U
Pipkorn
U
U
Persson
C G
CG
D000293:Adolescent; D000328:Adult; D000418:Albumins / Q000378:metabolism; D001798:Blood Proteins / Q000378:metabolism; D001920:Bradykinin / Q000378:metabolism; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002199:Capillary Permeability / Q000187:drug effects; D004311:Double-Blind Method; D005122:Exudates and Transudates / Q000187:drug effects*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006632:Histamine / Q000494:pharmacology*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009092:Mucous Membrane / Q000187:drug effects / Q000378:metabolism; D017817:Nasal Lavage Fluid; D013726:Terbutaline / Q000008:administration & dosage / Q000494:pharmacology; D013806:Theophylline / Q000008:administration & dosage / Q000494:pharmacology; D014970:Xanthines / Q000008:administration & dosage / Q000494:pharmacology
D000418:Albumins; D001798:Blood Proteins; D001993:Bronchodilator Agents; D014970:Xanthines; D006632:Histamine; D005340:Fibrinogen; D013806:Theophylline; C034347:enprofylline; D013726:Terbutaline; D001920:Bradykinin